Plasma suPAR may distinguish pancreatic cancer from a benign pancreatic disease

Objectives SuPAR (soluble urokinase plasminogen activator receptor) is a marker associated with systemic inflammation and certain malignant diseases. Previously we have shown that it is possible to predict the severity of acute alcohol-induced pancretitis (AAP) (Nikkola et  al. Pancreas 2017) and long-term survival after recovery from first AAP (Aronen et al. 2018, submitted) using P-suPAR levels. Urinary suPAR/creatinine ratio is elevated both in chronic pancreatitis (CP), and in pancreatic cancer (PC) (Sorio et al.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Anu Aronen, Janne Aittoniemi, Reetta Huttunen, Anssi Nikkola, Irina Rinta-Kiikka, Jussi Nikkola, Olli Limnell, Isto Nordback, Juhani Sand, Johanna Laukkarinen Tags: 8. Pancreatic Cancer I Source Type: research